<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48634">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01963728</url>
  </required_header>
  <id_info>
    <org_study_id>Inova NODAT-001</org_study_id>
    <nct_id>NCT01963728</nct_id>
  </id_info>
  <brief_title>Comparison of Insulin Therapy in Treating Post-Transplant Diabetes</brief_title>
  <official_title>Comparison of Insulin Isophane (NPH) With Insulin Glargine in New Onset Diabetes After Transplant (NODAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inova Health Care Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inova Health Care Services</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if the use of insulin isophane results in improved control of blood sugars
      compared to the use of insulin glargine in new onset diabetes after kidney, lung, or heart
      transplantation (NODAT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A large percentage of organ transplant recipients develop de novo diabetes mellitus after
      transplantation, also called &quot;New Onset Diabetes After Transplant&quot; or NODAT.  The cause of
      the diabetes appears to be commonly used anti-rejection medications, particularly
      calcineurin inhibitors and glucocorticoids.

      Management of glucose levels in NODAT often requires insulin therapy. Standard practice is
      to start long-acting insulin. However, patients with NODAT often exhibit fasting morning
      glucose levels that are relatively low compared to pre-lunch and pre-dinner glucose levels.
      This seems to make NODAT patients more susceptible to fasting, or morning, hypoglycemia on
      long-acting insulin analogues than non-transplant patients with type II diabetes. This
      phenomenon of morning hypoglycemia in NODAT often limits the up-titration of basal insulin
      resulting in suboptimal treatment of hyperglycemia later in the day. Because of this
      pattern, transplant patients may respond better to morning insulin isophane (intermediate
      acting) than to long-acting insulin glargine preparations.

      Our trial is designed to compare morning NPH insulin (isophane insulin) with conventional
      therapy of basal glargine insulin on both continuous blood glucose levels and hemoglobin A1c
      (glycosylated hemoglobin).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change in Hemoglobin A1C (glycosylated hemoglobin)</measure>
    <time_frame>at 3 monnths post enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>change in hemoglobin A1C (glycosylated hemoglobin)</measure>
    <time_frame>at 6 months post enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean blood glucose values</measure>
    <time_frame>3 and 6 months post enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>measured by continuous glucose monitoring for 5 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight change</measure>
    <time_frame>3 and 6 months post enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of hypoglycemic episodes per subject</measure>
    <time_frame>from the start of enrollment to subject completion of study at 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>insulin isophane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>daily dose will be titrated based on fasting morning glucose values</description>
  </arm_group>
  <arm_group>
    <arm_group_label>insulin glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>daily dose will be titrated based on fasting morning glucose values</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin, Isophane</intervention_name>
    <description>daily dosing based on fasting morning glucose levels</description>
    <arm_group_label>insulin isophane</arm_group_label>
    <other_name>human NPH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>daily dose based on fasting morning glucose levels</description>
    <arm_group_label>insulin glargine</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be followed by the Inova Fairfax Hospital transplantation program for
             post-transplant care

          2. Diabetes mellitus inadequately responsive to lifestyle modification and non-insulin
             hypoglycemic medication

          3. Need for subcutaneous insulin therapy (after discontinuation of IV insulin therapy,
             if it was required)

          4. Ability to read consent form and give consent in English.

        Exclusion Criteria:

          1. Use of insulin or non-insulin hypoglycemic medication before transplantation

          2. Cystic fibrosis patients

          3. Age &lt; 18 years of age

          4. Pregnancy

          5. Non-English speaking subjects
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Ross, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inova Healthcare Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renee Brenner, BS, CCRC</last_name>
    <phone>703-776-6147</phone>
    <email>renee.brenner@inova.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>A. Whitney Brown, MD</last_name>
    <phone>703-776-3156</phone>
    <email>Annw.brown@inova.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renee Brenner, BS, CCRC</last_name>
      <phone>703-776-6147</phone>
      <email>renee.brenner@inova.org</email>
    </contact>
    <contact_backup>
      <last_name>A. Whitney Brown, MD</last_name>
      <phone>703-776-3156</phone>
      <email>annw.brown@inova.org</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>A. Whitney Brown, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adam Cochran, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renee Brenner, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 4, 2013</lastchanged_date>
  <firstreceived_date>October 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post-transplant</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>renal transplant</keyword>
  <keyword>kidney transplant</keyword>
  <keyword>lung transplant</keyword>
  <keyword>heart transplant</keyword>
  <keyword>insulin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glargine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, NPH</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
